33
Views
3
CrossRef citations to date
0
Altmetric
Breast Cancer

Rare (new) entities of the breast and medullary carcinoma

&
Pages 48-56 | Received 23 Jun 2008, Accepted 03 Aug 2008, Published online: 06 Jul 2009
 

Summary

Rare tumours are a heterogeneous group of conditions that encompass benign to malignant lesions both of stromal and epithelial origin. Here some of these tumours are described, in which the authors have most familiarity. An outline of medullary carcinoma is also presented.

Abbreviations
ACC=

adenoid cystic carcinoma

ACCA=

acinic cell carcinoma

BTRTC=

breast tumours resembling the tall cell variant of papillary thyroid carcinoma

ILC=

invasive lobular carcinoma

LASC=

low grade adenosquamous carcinoma

LEC=

lymphoepithelioma-like carcinoma

MC=

medullary carcinoma

PLA=

polymorphous adenocarcinoma

PLGA=

polymorphous low grade adenocarcinoma

RD=

Rosai Dorfman disease

SyT=

syringomatous tumour of the nipple

Abbreviations
ACC=

adenoid cystic carcinoma

ACCA=

acinic cell carcinoma

BTRTC=

breast tumours resembling the tall cell variant of papillary thyroid carcinoma

ILC=

invasive lobular carcinoma

LASC=

low grade adenosquamous carcinoma

LEC=

lymphoepithelioma-like carcinoma

MC=

medullary carcinoma

PLA=

polymorphous adenocarcinoma

PLGA=

polymorphous low grade adenocarcinoma

RD=

Rosai Dorfman disease

SyT=

syringomatous tumour of the nipple

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.